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MOLECULAR SIGNATURES OF IN VITRO DRUG RESPONSE IN LUNG 
CANCER.  
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We are developing in vitro drug response signatures based on profiling of mRNA 
(Illumina WG6-V3 arrays), DNA mutation (COSMIC and deep sequencing), DNA copy 
number (Illumina Human1M-Duov3 SNP array) and DNA methylation (Illumina 
HumanMethylation450) from lung cancer cell lines to predict which drugs a patient's 
tumor is most likely to respond to. We have generated drug response phenotypes (MTS 
colorimetric assays) for 25 standard, targeted, and new chemotherapy agents and 
combinations for 100 non-small cell lung cancer (NSCLC) lines. All assays were done 
in triplicates or more and were very reproducible over time (r > 0.8). More than 10,000 
MTS assays were generated and we designed a high-throughput database software named 
DIVISA (Database of In VItro Sensitivity Assays) for the purpose of storing and 
analyzing these assays. Some drugs showed a wide range of sensitivities (> 10,000-fold 
in IC50 values) and IC50 clustering indicates that drug response phenotypes can be 
grouped according to drug types. As part of a joint NCI SPORE, NCI SPECS, and DOD 
PROSPECT effort we have collected 275 clinically annotated frozen tumors with drug 
response information including 94 that represent lung cancer resection followed by 
adjuvant treatment. These specimens have also been profiled on Illumina expression 
arrays to formally test the clinical relevance of the tumor cell line signatures, and to 
verify that the signatures predict for response only in the presence of treatment and thus 
are not prognostic of survival in the absence of treatment. In addition, we have 3 primary 
tumor datasets totaling 96 specimens with EGFR mutation information, thus providing a 
validation set for EGFR tyrosine kinase inhibitor signatures. Using a weighted voting 
classification, cell line signatures predicted drug response in primary tumors with 
accuracies of 65% for targeted therapy (EGFR) but with somewhat lower accuracies for 
platin/taxane therapies suggesting that cell line predictive signatures may be better suited 
for targeted drugs. To facilitate translation to clinical trials we are working with High 
Throughput Genomics (HTG) to develop quantitative mRNA profiles that are performed 
on formalin fixed paraffin embedded (FFPE) material on a platform that can be 
transferred to a CLIA certified environment. These studies thus provide a preclinical 
human tumor model platform for systematically testing new drugs and for developing 
signatures to guide their most efficient use in early clinical tests. 
